SLC5A1 and type 2 diabetes mellitus: Cardiovascular safety of the dual SGLT1/SGLT2 inhibitor sotagliflozin is being tested in the SCORED trial in patients with T2D, moderate renal impairment and high cardiovascular risk (NCT 03315143).